Morpholine orexin receptor antagonist

Novel compounds with specific structures targeting OX1 receptors offer improved treatment for disorders mediated by orexin receptors, enhancing selectivity and metabolic stability for treating CNS disorders, neurological disorders, and substance addictions.

JP2026524754APending Publication Date: 2026-07-24BIAL PORTELA & CA SA
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
BIAL PORTELA & CA SA
Filing Date
2024-07-22
Publication Date
2026-07-24

Smart Images

  • Figure 2026524754000001_ABST
    Figure 2026524754000001_ABST
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I) that are useful as orexin antagonists, or pharmaceutically acceptable salts, solvates, adducts, polymorphs, isomers and derivatives thereof, their preparation, their use in pharmaceutical compositions, and methods for treating or preventing diseases or disorders mediated by orexin receptor activity using orexin antagonists. JPEG2026524754000299.jpg39149
Need to check novelty before this filing date? Find Prior Art